Oxford Nanopore (LSE:ONT) Technologies, the British gene-sequencing company once feted as a rare home-grown deep-tech champion, has spent much of 2026 firmly back under the microscope. In mid-July the shares slumped around 16% to about 101 pence after a trading update revealed slower-than-expected first-half Revenue and, crucially, a trimming of its medium-term growth ambitions. For a Business whose valuation has always rested on the promise of rapid, compounding growth, any suggestion that the trajectory is flattening tends to be punished hard — and it was.
The proximate cause was geography. First-half revenue rose only about 10% on a reported basis (roughly 12% at constant currency), well short of what the market had been modelling. Sales in China fell around 16%, hit by tighter export-control restrictions and a reorganisation of the company's commercial operations there, while Middle East revenue dropped about 14% amid regional tensions. Strip out those two regions and underlying growth was closer to 16% at constant currency — a reminder that the core business is still expanding, even as external forces drag on the headline.
A tale of two updates
The story did not end with the July sell-off. When Oxford Nanopore (LSE:ONT) published full interim results on 19 August, the shares jumped about 16%, as investors shifted their attention from the top-line miss to a marked improvement in profitability. Revenue came in at £116.7 million, up 12.3% at constant currency, but the more striking figures were on margins and losses: gross Margin expanded around 400 basis points to 62.2%, and the adjusted EBITDA loss more than halved to £22.1 million from £48.3 million a year earlier. The company reaffirmed its path to adjusted EBITDA breakeven in 2027 and positive free Cash Flow in 2028.
That whipsaw captures the Investment debate around the stock. Oxford Nanopore's handheld and benchtop sequencers, based on distinctive nanopore technology that reads long strands of DNA and RNA in real time, have carved out a genuine niche against larger incumbents. The question has never been whether the technology works, but whether the company can grow revenue fast enough while narrowing losses to justify a valuation that has, at times, looked demanding. The August numbers suggested management is delivering on the cost and margin side; the July numbers underlined that growth remains lumpy and exposed to factors outside its control.
Risks and what to watch
For the full year, management guided to constant-currency revenue growth of 16-20% on an underlying basis (with a wider 21-25% range possible depending on one-off collaboration revenue), a gross margin of around 62%, and reiterated its profitability milestones. Cash and liquid investments stood at £234.5 million at the end of June, down from £302.8 million at the start of the year — a comfortable but finite runway that makes the march towards breakeven the single most important metric for investors.
The risks are clear. China and geopolitics remain a swing Factor that management cannot fully control, and export restrictions on advanced technology could tighten further. Competition from established sequencing firms is intense, and the company is still loss-making, which leaves it sensitive to any slippage in its cost-reduction plans. Sentiment towards unprofitable Growth Stocks has also been volatile, amplifying share-price moves in both directions.
What comes next hinges on execution: sustaining double-digit constant-currency growth in the core business, stabilising China, and hitting the 2027 breakeven target without burning through the cash pile. The August rebound showed the market will reward evidence of financial discipline. But after a year of sharp swings, Oxford Nanopore still has to prove that its impressive technology can translate into the durable, profitable growth its long-term backers were promised.






Please wait processing your request...